



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2016

Pseudotyping serotype 5 adenovirus with the fiber from other serotypes uncovers a key role of the fiber protein in adenovirus 5-induced thrombocytopenia

Raddi, Najat ; Vigant, Frédéric ; Wagner-Ballon, Oriane ; Giraudier, Stéphane ; Custers, Jerome ; Hemmi, Silvio ; Benihoud, Karim

DOI: <https://doi.org/10.1089/hum.2015.154>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-134533>

Journal Article

Accepted Version

Originally published at:

Raddi, Najat; Vigant, Frédéric; Wagner-Ballon, Oriane; Giraudier, Stéphane; Custers, Jerome; Hemmi, Silvio; Benihoud, Karim (2016). Pseudotyping serotype 5 adenovirus with the fiber from other serotypes uncovers a key role of the fiber protein in adenovirus 5-induced thrombocytopenia. *Human Gene Therapy*, 27(2):193-201.

DOI: <https://doi.org/10.1089/hum.2015.154>

Pseudotyping Serotype 5 Adenovirus with the Fiber from Other Serotypes Uncovers a Key Role of the Fiber Protein in Adenovirus 5-Induced Thrombocytopenia

Najat Raddi,¹ Frédéric Vigant,^{1,†} Oriane Wagner-Ballon,^{2,3} Stéphane Giraudier,^{2,3} Jerome Custers,⁴ Silvio Hemmi,⁵ and Karim Benihoud^{1,*}

¹UMR 8203 Vectorologie et Thérapeutiques Anticancéreuses, CNRS, Univ. Paris-Sud, Gustave Roussy, Université Paris-Saclay, Villejuif, France; ²Inserm, U1009, Université Paris-Sud11, Villejuif, France; ³Assistance Publique des Hôpitaux de Paris, Laboratoire d'Hématologie, Université Paris-Est Créteil, Hôpital Henri Mondor, Créteil, France; ⁴Viral Vaccine Discovery and Early Development, Crucell Holland BV, Leiden, The Netherlands; ⁵Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.

[†]Present address: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York.

Adenovirus (Ad) infection in humans is associated with inflammatory responses and thrombocytopenia. Although several studies were conducted in mice models to understand molecular and cellular mechanisms of Ad-induced inflammatory responses, only few of them turned their interest toward the mechanisms of Ad-induced thrombocytopenia. Using different depletion methods, the present study ruled out any significant role of spleen, macrophages, and vitamin K-dependent factor in Ad-induced thrombocytopenia. Interestingly, mice displaying thrombocytopenia expressed high levels of cytokines/chemokines after Ad administration. Most importantly, pseudotyping adenovirus with the fiber protein from other serotypes was associated with reduction of both cytokine/chemokine production and thrombocytopenia. Altogether, our results suggest that capsid fiber protein (and more precisely its shaft) of Ad serotype 5 triggers the cytokine production that leads to Ad-induced thrombocytopenia.

INTRODUCTION

ADENOVIRUSES (AD) CORRESPOND TO a large family of nonenveloped viruses. Among them, human Ad from serotype 5 (Ad5), responsible for mild lung disease, is the best characterized and has been engineered to derive vectors that are attractive tools for gene therapy. These vectors contain a core surrounded by a capsid mainly composed by hexon, fiber, and penton base proteins. Ad5 cell infection *in vitro* occurs first *via* fiber protein knob binding to the Coxsackie and Ad receptor also known as CAR.¹ Then, integrins acting as coreceptors interact with the virus through an RGD motif of the penton base protein to facilitate virus internalization.²

Direct vector administration into the bloodstream is associated with several toxicities and acute responses. For example, a strong hepatic tropism leads to liver toxicity and damages.^{3,4} The liver transduction was linked to the ability of Ad hexon protein to interact with coagulation factor X (FX),

allowing subsequent virus binding to heparan sulfate proteoglycans expressed on hepatocytes.⁵⁻⁷ Interestingly, several studies have reported that mutations of the main capsid components or their replacement by proteins from other Ad serotypes also result in reduced hepatocyte transduction.⁸⁻¹² Besides liver toxicity, the triggering of an acute inflammatory response and cytokine production within hours after virus administration represents one of the major hurdles to Ad gene therapy.⁶

Once into the bloodstream, Ad can interact with many circulating blood cells, including human erythrocytes,¹³ peripheral blood mononuclear cells,¹⁴ neutrophils,¹⁵ dendritic cells,¹⁶ and platelets.¹⁷ Particularly, an important decrease in platelet count known as thrombocytopenia was associated with Ad infection, both in preclinical studies¹⁸ and in clinical trials.¹⁹⁻²¹ How Ad trigger thrombocytopenia is still poorly understood. Some studies have demonstrated that Ad can bind directly to platelets and trigger their

*Correspondence: Prof. Karim Benihoud, CNRS UMR 8203 Vectorologie et Thérapeutiques Anticancéreuses, Gustave Roussy, 114, rue Edouard Vaillant, 94 805 Villejuif, France. E-mail: karim.benihoud@gustaveroussy.fr

activation and aggregation both *in vitro* and *in vivo*.^{17,22} In contrast, another study reported that Ad is not able to interfere with or potentiate platelet aggregation.²³ The involvement of Ad primary receptor CAR and integrins in platelet interaction is also controversial. Indeed, two conflicting results were obtained regarding CAR expression on human platelets.^{22,24} Finally, although different integrin ligands were able to block Ad binding to platelets *in vitro*,²² a recent study questioned the role of integrins because blocking α IIb β 3 and α v β 3 integrins does not modify Ad binding and activation of platelets.²⁵ Studies of Ad-induced thrombocytopenia in different knockout (KO) mouse models helped to identify the role of specific soluble host factors. For example, Ad administration in Von Willebrand factor (VWF) KO mice did not trigger a significant thrombocytopenia compared with wild-type (wt) mice, thereby suggesting a key role of VWF in Ad-associated thrombocytopenia.²⁶ Also, the lack of thrombocytopenia in mice deficient for C3 and factor B proteins suggests a role for these complement factors in this phenomenon.²⁷ Finally, both genetic and acquired (pretreatment with neutralizing antibodies) deficiencies in TNF- α improved Ad-induced thrombocytopenia, suggesting a role for TNF- α pathway in this phenomenon.²⁸

In the present study, we seek to go deeper in the understanding of viral and host factors at the origin of Ad-induced thrombocytopenia. Most strikingly, we report a role of Ad5 fiber protein in Ad-induced thrombocytopenia.

MATERIALS AND METHODS

Adenovirus

Adwt and AdF3 were previously described⁹ and derived from Ad5 with E1 and E3 regions deleted. AdS3K5 was obtained by replacing Ad5 shaft (amino acid residues 47–400) by Ad3 shaft (amino acid residues 46–132). All viruses contain an expression cassette with the promoter/enhancer from the immediate early gene of human cytomegalovirus (CMV), the *Escherichia coli lacZ* gene with a nuclear localization signal, and the SV40 late polyA signal. eGFP recombinant and E1-deleted serotype 3 (Ad3) was described previously.²⁹ Luciferase recombinant Ad pseudotyped with fiber from serotype 35 (AdF35) was described previously.³⁰ All viruses were obtained using standard procedures as described,³¹ stored at -80°C in PBS and 7% glycerol, and titrated by spectrophotometry ($1 \text{ OD}_{260} = 1.1 \times 10^{12}$ viral particles [vp]/ml).

In vivo experiments

All animal experimental procedures were conducted in accordance with the institutional guidelines of Gustave Roussy Institutional Animal Care and Use Committee. Six- to eight-week-old female C57BL/6 (Harlan, France) mice were intravenously (i.v.) injected into the retro-orbital plexus with 5×10^{10} , 10^{11} , or 2×10^{11} vp of corresponding vectors. Blood from the retro-orbital plexus of mice was collected in citrated tubes at the indicated time points after virus administration. Platelets were counted using an automated counter of blood cells (MS9; Schloessing Melet).

For mice splenectomy, C57BL/6 mice were anesthetized and the lateral area of the animal left side was shaved. A 3–4 cm incision was made and the spleen was removed from the visceral cavity and the blood vessels were cauterized. Five days later, mice were i.v. injected with Ad and platelets were counted 2 days later as described above.

Kupffer cell and coagulation factor depletion

Two approaches were used to induce Kupffer cells (KC) depletion. The predosing method consists of injection of 3×10^{10} vp of AdGFP 4 hr before vector administration.³² KC depletion was alternatively induced with intravenous administration of 200 μl of clodronate-liposomes or PBS-liposomes as negative control 24 hr before Ad administration. Transient KC elimination was confirmed by liver section immunolabelling with F4/80 antibody. For coagulation factor depletion, mice were injected subcutaneously with 133 μg of warfarin in 100 μl of PBS at 3 and 1 day before Ad delivery as previously described.⁵

Cytokine and chemokine measurement

Spleens harvested 1 hr after intravenous Ad administration (10^{11} vp) were homogenized in sample buffer according to manufacturer's instructions. Lysates were incubated overnight with membranes from Proteome Profiler Antibody array (Mouse Cytokine Array Panel A; R&D System) according to manufacturer's instructions. Membranes were developed with HRP substrate and revealed using ChemiDoc MP System (BioRad).

Interleukin-6 measurement

Blood samples were collected 6 hr after Ad administration and serum interleukin-6 (IL-6) was quantified using a Duo-Set ELISA assay according to manufacturer's instructions (R&D).

FX measurement

Endogenous murine FX activity was determined by an amidolytic assay using the Russel's Viper

Venom-X enzyme (RVV-X). In this assay, FX activation into FXa by the RVV-X leads to the cleavage of the chromogenic substrate S-2765. Briefly, plasma samples or a pool of plasma from wt C57BL/6 mice (used as standard) were diluted in TBS/BSA (0.1%)/CaCl₂ (5 mM) and incubated with 0.5 μ M RVV-X enzyme (Kordia Life Science) 5 min at 37°C. The chromogenic substrate S-2765 (Chromogenix) was added at 0.2 mM and the kinetic reading at 405 nm was immediately started with a reading every 30 sec over 20 min. The V_{max} (maximum speed of chromogenic conversion) was calculated for the linear part of the kinetic curve and plasma sample values were normalized to the standard. FX activity was expressed in units/ml.

Statistical analysis

Results were expressed as means \pm SEM. ANOVA analysis followed by Tukey's *post-hoc* test was used to compare sets of data. Variations were considered statistically significant when $p < 0.05$. All graphs and statistical tests were performed using GraphPad Prism software.

RESULTS AND DISCUSSION

Kinetics and dose dependency of Ad-induced thrombocytopenia

First, we sought to determine the kinetics of thrombocytopenia induction in response to Ad administration. C57BL/6 mice were i.v. injected with saline or two different doses of Ad (10^{11} and 2×10^{11} vp), and platelet counts were determined every day during the first week and at day 15 postinfection (p.i.) (Fig. 1). Ad injection caused a rapid decrease in platelet count within 24 hr p.i. with a nadir at 48 hr p.i.. Of note, the reduction in platelet count was more severe with the higher viral dose, demonstrating the dose dependency of this phenomenon (Fig. 1). However, the thrombocytopenia was transient and mice recovered a normal platelet count by day 5 p.i.. The kinetic of thrombocytopenia induction and the dose dependency observed in our study are in accordance with previous results obtained by others in mice³³ but also in rabbits,³³ baboons,³⁴ and rhesus monkeys.¹⁸

Blood coagulation factors and spleen are not involved in Ad-induced thrombocytopenia

Coagulation factors and platelet activation are complementary and mutually dependent processes participating in hemostasis.³⁵ Because Ad is able to interact with different blood factors such as coagulation factor IX and X (FX),⁵ we evaluated whether these factors play a role in Ad-induced




Figure 1. Kinetics of Ad-induced thrombocytopenia. Mice were injected intravenously with PBS or with different doses (10^{11} and 2×10^{11} vp) of Adwt. Platelet counts were determined at different time points thereafter. $n = 5$ mice; means \pm SEM. Ad, adenovirus; Adwt, Ad bearing a wild-type capsid.

thrombocytopenia. To answer this question, C57BL/6 mice were pretreated with warfarin or saline at days 3 and 1 before Ad administration, as described previously.⁵ Blood factor depletion was confirmed by the measurement of FX activity in mice sera harvested before virus delivery (12.8 ± 3.2 in warfarin-treated mice vs. 187.9 ± 54.7 in PBS-treated mice). After Ad administration of 2×10^{11} (Fig. 2a) or 10^{11} vp (Fig. 2b), no statistically significant difference in platelet counts was observed between saline- or warfarin-pretreated mice. These results ruled out any significant role of coagulation factors in Ad-induced thrombocytopenia and are in accordance with the fact that hexon-modified Ad that are disabled in FX interaction triggered thrombocytopenia as efficiently as their wt counterparts.⁸ Then, we analyzed the spleen involvement in Ad-induced thrombocytopenia. Indeed, the spleen is well-known as a site of platelet storage able to release them upon request.³⁶ In addition, this organ removes old platelets from the bloodstream.³⁷ To assess the role of the spleen in Ad-induced thrombocytopenia, C57BL/6 mice were splenectomized or sham-treated 5 days before Ad systemic administration, and platelet counts were determined 48 hr p.i. Both splenectomized and nonsplenectomized mice displayed a similar reduction in platelet numbers in response to Ad administration (Fig. 2c). In parallel, because the spleen can store excessive numbers of platelets leading to splenomegaly,³⁷ we carefully examined the size of the spleens of nonsplenectomized mice and did not observe signs of splenomegaly at day 2 after Ad




Figure 2. Coagulation factor and spleen involvement in Ad-induced thrombocytopenia. Mice were mock-treated (noninfected, NI) or treated with warfarin before injection of 2×10^{11} (a) or 10^{11} vp (b) of Adwt, and platelet counts were determined 2 days later. (c) C57B/6 mice were splenectomized or sham-splenectomized 5 days before injection of Adwt (10^{11} vp) and platelet numbers were counted 2 days later. $n=2-5$ mice; means + SEM. ** $p < 0.01$ and *** $p < 0.001$ versus NI matched, treated control. ns, nonsignificant.

administration (data not shown). Taken together, these results demonstrated no significant role of the spleen in Ad-induced thrombocytopenia. In contrast, Hofherr et al. reported that splenectomy protected mice from Ad-induced thrombocytopenia.³ The discrepancy between our results and Hofherr et al. could be because of differences in mice strains (C57BL/6 in our study and outbred ICR mice in the study of Hofherr et al.) and viral doses used.

Requirement of the fiber shaft in Ad5-induced thrombocytopenia

To address the question of viral proteins involved in Ad-induced thrombocytopenia, we focused on capsid proteins known to participate in Ad infection process. These proteins correspond to hexon, penton base, and fiber proteins able to bind to coagulation FX, integrins, CAR and heparan sulfates, respectively. First, we ruled out a role for hexon–FX interaction in Ad-induced thrombocytopenia because we reported previously that impairing hexon binding to FX has no impact on platelet counts.⁸ Second, previous data from our laboratory based on the use of Ad disabled in integrin interaction ruled out any role for the penton base protein in Ad-induced thrombocytopenia (data not shown). Then, taking advantage of the two already described serotype 5 recombinant Ad pseudotyped with the fiber from serotype 3 (Vigne et al.⁹ and Raddi et al., unpublished manuscript), we investigated the role of the fiber protein. C57BL/6 mice were injected i.v. with a high (Fig. 3a), intermediate (Fig. 3b), or low (Supplementary Fig. S1; Supplementary Data are available online at www.liebertpub.com/hum) dose of Adwt, AdF3, or AdS3K5. Both latter viruses express the

whole (shaft and knob) or only the shaft of Ad3 fiber, respectively. Whereas Adwt triggered a strong drop in platelet counts, fiber-modified Ads triggered a significantly reduced thrombocytopenia even at the highest viral dose (Fig. 3a). Interestingly, although Adwt still induced platelet reduction at the lowest dose of 5×10^{10} vp, fiber-modified Ad did not (Supplementary Fig. S1).

These results suggest that either Ad5 fiber was responsible for the induction of the thrombocytopenia or Ad3 fiber has an intrinsic property to mitigate thrombocytopenia. To decipher between these two hypotheses, C57BL/6 mice were injected with 10^{11} vp of Adwt or a recombinant Ad3. Figure 3c shows that Ad3 induces thrombocytopenia to the same extent as Adwt does, thus ruling out a modulatory role of Ad3 fiber. On the other hand, pseudotyping Ad5 with a fiber from serotype 35 (AdF35) strongly reduced virus-induced thrombocytopenia (Fig. 3d). Altogether, these results suggest that Ad5 fiber was involved in Ad-induced thrombocytopenia. More precisely, because AdS3K5 also displayed a reduced thrombocytopenia, this indicates a role for the Ad5 shaft in this phenomenon. The fact that thrombocytopenia was observed in clinical trials after administration of an Ad pseudotyped with a chimeric fiber containing Ad5 shaft and Ad3 knob further supports our conclusions.³⁸ However, it should be underlined that Ad displaying a targeting peptide within the HI loop also led to a reduced thrombocytopenia.³⁹ The discrepancy between our results (role of the shaft) and their results (role of the knob) may be linked to the different strains of mice (C57BL/6 and BALB/c, respectively) used or alternatively to the targeting ligand used in Coughlan et al.³⁹




Figure 3. Thrombocytopenia induction by fiber-modified Ad5 and Ad3. Mice were intravenously injected with 2×10^{11} (a) or 10^{11} (b–d) vp of serotype 5 Ad bearing a wild-type capsid (Adwt) or pseudotyped with AdF3 (a, b) or AdF35 fiber (d), or of serotype 3 Ad3 (c). Platelet counts were determined 2 days later. A representative experiment out of three repeats is shown. $n=4-7$ mice; means + SEM. $**p < 0.01$ and $***p < 0.001$ versus Adwt (a, b, d) or control group (c).

Role of macrophages in Ad5-induced thrombocytopenia

Different pathogens are able to interact with platelets, leading to their uptake by liver KC.⁴⁰ Whether or not Ad interact with platelets^{17,22,23}

and whether KC play any role in platelet clearance during virus infection^{17,41} are still a matter of debate. Therefore, we investigated the potential role of KC in the development of Ad-induced thrombocytopenia using two depletion methods: predos-




Figure 4. Role of Kupffer cells (KC) in Ad-induced thrombocytopenia. Mice were pretreated with or without Ad (predosing, a, b) or pretreated with PBS- or clodronate-liposomes (c, d). After 4 or 24 hr, respectively, mice were injected with PBS or with 10^{11} vp of Adwt, AdF3, or AdS3K5. Platelet counts were determined 2 days later and expressed relative to noninfected (NI) mice. One of two repeat experiments is shown; means and data for individual mice are shown. $*p < 0.05$, $**p < 0.01$, and $***p < 0.001$ versus NI group; ns, nonsignificant.

ing,³² which consists of preadministration of a low dose of Ad (3×10^{10} vp) able to specifically eliminate KC, the resident liver macrophages, or pretreatment with clodronate-liposomes that depletes any macrophages.⁴² Regardless of the depletion method, comparison of platelet counts in control (Fig. 4a and c) and in macrophage-depleted mice (Fig. 4b and d) did not show any significant modification of Adwt-induced thrombocytopenia. However, both methods of depletion were able to abrogate the modest reduction in platelet counts observed after intravenous AdF3 or AdS3K5 delivery. Thus, al-

though macrophages do not appear to play a significant role in Adwt-induced thrombocytopenia, they may play a role in the modest thrombocytopenia triggered by Ad pseudotyped with Ad3 fiber.

Reduced inflammatory responses triggered by Ad5 pseudotyped with the fiber from other serotypes

Different studies have proposed that cytokine production participates to Ad-induced thrombocytopenia.^{28,43,44} Therefore, we analyzed whether pseudotyping Ad5 with the fiber of serotype 3




Figure 5. Cytokine and chemokine production in response to Ad injection. Mice were intravenously injected with 10^{11} vp. **(a)** Spleen cytokine and chemokine differentially induced 1 hr postinfection in Adwt-injected mice compared with PBS-injected mice are shown for Adwt, AdF3, and AdS3K5. For each Ad, data of two mice are displayed. **(b–d)** Serum IL-6 production was determined by ELISA 6 hr after injection of Adwt, AdF3, AdS3K5 (10^{11} and 2×10^{11} vp, **b**), Ad3 (10^{11} vp, **c**), or AdF35 (10^{11} vp, **d**). One representative of two experiments is shown. $n=4-7$, means + SEM. *** $p < 0.001$ versus noninfected (NI) group; n.s., nonsignificant.

modifies cytokine and chemokine production in response to intravenous Ad delivery. First, using antibody arrays, we measured cytokine and chemokine production in the spleen harvested 1 hr p.i. (Fig. 5a). Compared with PBS-injected mice, Adwt-injected mice displayed a strong production of cytokines (IL-1 β and IL-6), chemokines (IP-10, KC, CCL2, CCL3, and CXCL2), as well as complement factor C5a and triggered receptor expressed on myeloid cells-1 (TREM-1). Interestingly, AdF3 and AdS3K5 induced a weak production of these cytokines and chemokines in the spleen, comparable to the one observed in the spleen from PBS-injected mice (Fig. 5a). Using ELISA, we observed a strong dose-dependent release of IL-6 in the blood 6 hr after Adwt administration. However, both AdF3- and AdS3K5-injected mice displayed a dramatic reduction in IL-6 production (Fig. 5b), at both viral doses. To exclude a putative inhibitory effect of Ad3 fiber (and more precisely Ad3 shaft) on inflammatory responses, C57BL/6 mice were injected with Adwt or Ad3. As shown in Fig. 5c, compared with Adwt, Ad3 led to a 20-fold higher production of serum IL-6 (Fig. 5c), ruling out a role for Ad3 fiber in decreasing cytokine and chemokine production. The fact that AdF3 and AdS3K5, on the one hand, and Ad3, on the other hand, present opposite capabilities to trigger cytokine production and thrombocytopenia is puzzling. One hypothesis would be that Ad3 shaft alone does not possess the intrinsic property to trigger cytokine production and thrombocytopenia but needs other Ad3 capsomers. An alternative hypothesis would be that insertion of fiber from serotype 3 in Ad5 backbone led to a particle trafficking different from Ad5, thus impairing cytokine production. Interestingly, intravenous administration of AdF35 led to serum IL-6 levels comparable to noninfected mice (Fig. 5d).

Taken as a whole, our results argue for a role of Ad5 shaft in cytokine and chemokine production. These results are further supported by a previous work showing that pseudotyping Ad5 with fiber from serotypes 11 or 35 reduced IL-6 and TNF- α production.⁴⁵

Ad-induced thrombocytopenia is associated with cytokine production

As stated above, Ad was reported by different teams⁴⁶ to trigger inflammatory cytokines production as well as thrombocytopenia. Our present results uncover that pseudotyping Ad5 with fibers from other serotypes (Ad3 or Ad35) both reduces cytokine production (Fig. 5) and ameliorates the thrombocytopenia (Fig. 3). This suggests an unanticipated link between cytokine production and thrombocytopenia. Interestingly, a point-by-point comparison of IL-6 production and platelet counts in individual mice demonstrated that Adwt-injected mice displayed both high levels of serum IL-6 and a reduction in platelet counts, whereas mice injected with pseudotyped Ad exhibit reduced level of IL-6 and high platelet counts (Fig. 6a and b). However, our previous results showed that thrombocytopenia occurred even in Ad-injected IL-6-deficient mice.⁴⁷ Taken together, these results point out that IL-6 itself is not mandatory to this phenomenon and suggests a role for other cytokines.

To summarize, taking advantage of various vectors (serotypes or pseudotyped Ad), we demonstrated a role for Ad5-fiber protein and more precisely for its shaft in Ad5-induced thrombocytopenia. We also reported that coagulation factors, spleen, and macrophages were dispensable in this phenomenon. In parallel, our results suggest that Ad5 fiber—more precisely Ad5 shaft—plays a key




Figure 6. Relationship between IL-6 levels in mice sera and platelet counts. (a) Mice were injected with 10^{11} or 2×10^{11} vp of Adwt, AdS3K5, and AdF3. (b) Mice were injected with 10^{11} vp of Adwt or AdF35. Serum IL-6 levels and blood platelet counts were measured 6 and 48 hr postinfection, respectively. Each dot represents results from an individual mouse.

role in induction of chemokines and cytokines. Interestingly, we draw a parallel between cytokine/chemokine production and thrombocytopenia. Indeed, using different Ads, our results show that Ads able to trigger high levels of cytokines do elicit strong thrombocytopenia. Mice injected with AdF3 and AdS3K5 displayed a reduction in C5a production (Fig. 5a), suggesting a reduced activation of the complement cascade. Since the complement activation was proposed by others to be involved in thrombocytopenia,⁴⁸ the low C5a production in the spleen of AdF3- and AdS3K5-injected mice could explain their inability to induce thrombocytopenia. Further experiments are needed to better understand the link between cytokine production, complement factors, and thrombocytopenia. By showing the key role of the Ad5 fiber protein in both cytokine production and thrombocytopenia, this study paves the way to a better understanding of molecular and cellular mechanisms involved in Ad-induced thrombocytopenia. Previous results of our laboratory have shown that fiber-pseudotyped Ad led to a reduced liver transduction upon intravenous delivery but to efficient tumor gene transfer upon direct intratumoral administration (Raddi

et al. unpublished manuscript). Altogether, the results underline that fiber-pseudotyped Ad that elicit low cytokine/chemokine production and reduced thrombocytopenia constitute tools of valuable interest for safer gene delivery in tumors.

ACKNOWLEDGMENTS

We are very grateful to the staff of the animal facility of Gustave Roussy for technical help. We also thank Olivier Christophe and Mohamad Kurdi for FX measurement. This work was supported by Centre National de la Recherche Scientifique, University Paris-Sud, INCa (PIMRANIS project), and EDF. N.R. and F.V. received fellowships from the Ministère de la Recherche et de la Technologie. N.R. received an additional fellowship from University Paris-Sud, and F.V. additional fellowships from the AFM and the Société Française d'Hématologie.

AUTHOR DISCLOSURE

The authors have no competitive financial interests to declare.

REFERENCES

- Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. *Science* 1997; 275:1320–1323.
- Wickham TJ, Mathias P, Cheresh DA, et al. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. *Cell* 1993;73:309–319.
- Hofherr SE, Mok H, Gushiken FC, et al. Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. *Hum Gene Ther* 2007;18:837–848.
- Lozier JN, Metzger ME, Donahue RE, et al. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. *Blood* 1999;94: 3968–3975.
- Parker AL, Waddington SN, Nicol CG, et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. *Blood* 2006;108:2554–2561.
- Baker AH, McVey JH, Waddington SN, et al. The influence of blood on *in vivo* adenovirus biodistribution and transduction. *Mol Ther* 2007;15: 1410–1416.
- Waddington SN, McVey JH, Bhella D, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. *Cell* 2008;132:397–409.
- Vigant F, Descamps D, Jullienne B, et al. Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. *Mol Ther* 2008; 16:1474–1480.
- Vigne E, Dedieu JF, Brie A, et al. Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation. *Gene Ther* 2003;10: 153–162.
- Alba R, Bradshaw AC, Parker AL, et al. Identification of coagulation factor (FX) binding sites on the adenovirus serotype 5 hexon: Effect of mutagenesis on FX interactions and gene transfer. *Blood* 2009;114:965–971.
- Waddington SN, Parker AL, Havenga M, et al. Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors *in vivo*: Fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. *J Virol* 2007;81:9568–9571.
- Short JJ, Rivera AA, Wu H, et al. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy. *Mol Cancer Ther* 2010;9:2536–2544.
- Cichon G, Boeckh-Herwig S, Kuemin D, et al. Titer determination of Ad5 in blood: A cautionary note. *Gene Ther* 2003;10:1012–1017.
- Higginbotham JN, Seth P, Blaese RM, et al. The release of inflammatory cytokines from human peripheral blood mononuclear cells *in vitro* following exposure to adenovirus variants and capsid. *Hum Gene Ther* 2002;13:129–141.
- Cotter MJ, Zaiss AK, Muruve DA. Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1. *J Virol* 2005;79:14622–14631.
- Lore K, Adams WC, Havenga MJ, et al. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. *J Immunol* 2007;179:1721–1729.
- Stone D, Liu Y, Shayakhmetov D, et al. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. *J Virol* 2007;81:4866–4871.
- Wolins N, Lozier J, Eggerman TL, et al. Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing *in vivo* platelet clearance. *Br J Haematol* 2003;123:903–905.
- Sung MW, Yeh HC, Thung SN, et al. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: Results of a phase I clinical trial. *Mol Ther* 2001;4:182–191.
- Raper SE, Yudkoff M, Chirmule N, et al. A pilot study of *in vivo* liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. *Hum Gene Ther* 2002;13: 163–175.

21. Li JL, Liu HL, Zhang XR, et al. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. *Gene Ther* 2009;16:376–382.
22. Shimony N, Elkin G, Kolodkin-Gal D, et al. Analysis of adenoviral attachment to human platelets. *Virology* 2009;6:25.
23. Eggerman TL, Mondoro TH, Lozier JN, et al. Adenoviral vectors do not induce, inhibit, or potentiate human platelet aggregation. *Hum Gene Ther* 2002;13:125–128.
24. Gupalo E, Buriachkovskaia L, Othman M. Human platelets express CAR with localization at the sites of intercellular interaction. *Virology* 2011;8:456.
25. Gupalo E, Kuk C, Qadura M, et al. Platelet-adenovirus vs. inert particles interaction: Effect on aggregation and the role of platelet membrane receptors. *Platelets* 2013;24:383–391.
26. Othman M, Labelle A, Mazzetti I, et al. Adenovirus-induced thrombocytopenia: The role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. *Blood* 2007;109:2832–2839.
27. Appledorn DM, McBride A, Seregin S, et al. Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors. *Gene Ther* 2008;15:1606–1617.
28. Mane VP, Toietta G, McCormack WM, et al. Modulation of TNF α , a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors. *Gene Ther* 2006;13:1272–1280.
29. Sirena D, Ruzsics Z, Schaffner W, et al. The nucleotide sequence and a first generation gene transfer vector of species B human adenovirus serotype 3. *Virology* 2005;343:283–298.
30. Lecollinet S, Gavard F, Havenga MJ, et al. Improved gene delivery to intestinal mucosa by adenoviral vectors bearing subgroup B and d fibers. *J Virol* 2006;80:2747–2759.
31. Martin K, Brie A, Saulnier P, et al. Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. *Mol Ther* 2003;8:485–494.
32. Manickan E, Smith JS, Tian J, et al. Rapid Kupffer cell death after intravenous injection of adenovirus vectors. *Mol Ther* 2006;13:108–117.
33. Cichon G, Schmidt HH, Benhidjeb T, et al. Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits. *J Gene Med* 1999;1:360–371.
34. Morral N, O'Neal WK, Rice K, et al. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. *Hum Gene Ther* 2002;13:143–154.
35. Berndt MC, Metharom P, Andrews RK. Primary haemostasis: Newer insights. *Haemophilia* 2014;20 Suppl 4:15–22.
36. Wadenvik H, Kutti J. The spleen and pooling of blood cells. *Eur J Haematol* 1988;41:1–5.
37. Aster RH. Studies of the fate of platelets in rats and man. *Blood* 1969;34:117–128.
38. Pesonen S, Nokisalmi P, Escutenaire S, et al. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. *Gene Ther* 2010;17:892–904.
39. Coughlan L, Vallath S, Gros A, et al. Combined fiber modifications both to target alpha(v)beta(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles *in vivo* but fail to improve antitumoral efficacy relative to adenovirus serotype 5. *Hum Gene Ther* 2012;23:960–979.
40. Wong CH, Jenne CN, Petri B, et al. Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. *Nat Immunol* 2013;14:785–792.
41. Xu Z, Tian J, Smith JS, et al. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. *J Virol* 2008;82:11705–11713.
42. van Rooijen N, Bakker J, Sanders A. Transient suppression of macrophage functions by liposome-encapsulated drugs. *Trends Biotechnol* 1997;15:178–185.
43. De Geest B, Snoeys J, Van Linthout S, et al. Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. *Hum Gene Ther* 2005;16:1439–1451.
44. Seregin SS, Appledorn DM, McBride AJ, et al. Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. *Mol Ther* 2009;17:685–696.
45. Ni S, Gaggari A, Di Paolo N, et al. Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting. *Cancer Gene Ther* 2006;13:1072–1081.
46. Descamps D, Benihoud K. Two key challenges for effective adenovirus-mediated liver gene therapy: Innate immune responses and hepatocyte-specific transduction. *Curr Gene Ther* 2009;9:115–127.
47. Benihoud K, Salone B, Esselin S, et al. The role of IL-6 in the inflammatory and humoral response to adenoviral vectors. *J Gene Med* 2000;2:194–203.
48. Kiang A, Hartman ZC, Everett RS, et al. Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. *Mol Ther* 2006;14:588–598.

Received for publication November 25, 2015;
accepted after revision January 8, 2016.

Published online: January 11, 2016.